Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02904096 · ClinicalTrials.gov registry record · NA

Radiesse® Safety Study For the Treatment of Hands

A NA study of Volume Loss in the Dorsum of the Hand, sponsored by Merz North America.

Completed
Registry status
NA
Development phase
256
Enrollment target
9
Study locations

NCT02904096 is a NA study of Volume Loss in the Dorsum of the Hand that has completed, run by Merz North America. The registered enrollment target is 256 participants. The trial reports 9 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02904096, a NA study of Volume Loss in the Dorsum of the Hand, has completed, sponsored by Merz North America.

COMPLETED
Registry status
NA
Development phase
256 participants
Enrollment target
9
Study locations

Study Summary

The primary objective of this study is to evaluate the safety of Radiesse implantation for very severe volume loss in the dorsum of the hand at 6 months after treatment.

Interventions

  • DEVICE Radiesse injectable implant and 2% lidocaine HCL

Study Locations (9)

California

  • Merz Investigative Site #0010393 - Sacramento
  • Merz Investigative Site #0010321 - San Diego
  • Merz Investigative Site #0010358 - Vista
  • Merz Investigative Site #0010099 - West Hollywood

New York

  • Merz Investigative Site #0010405 - New York
  • Merz Investigative Site #0010406 - New York

Texas

  • Merz Investigative Site #0010322 - Austin
  • Merz Investigative Site #0010125 - Plano

Washington

  • Merz Investigative Site #0010392 - Spokane

Trial Details

FieldValue
Enrollment Target 256 participants
Start Date 2016-06-10
Est. Completion 2019-01-09
Phase NA

Sponsor

Merz North America

35 total trials

What the Registry Record Tells You About NCT02904096

The ClinicalTrials.gov registry entry for NCT02904096 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merz North America, which has 35 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Volume Loss in the Dorsum of the Hand appearing as the primary indexed condition, and to 1 intervention - of which Radiesse injectable implant and 2% lidocaine HCL is the first listed.

NCT02904096 reports 9 study locations spanning 4 distinct geographic areas - top geographies include California, New York, Texas.

Frequently Asked Questions

What is clinical trial NCT02904096 about?

NCT02904096 is a clinical study titled "Radiesse® Safety Study For the Treatment of Hands". The primary objective of this study is to evaluate the safety of Radiesse implantation for very severe volume loss in the dorsum of the hand at 6 months after treatment.

What is the current status of trial NCT02904096?

This trial is currently completed. It is a NA study. The enrollment target is 256 participants. The study started on 2016-06-10. Estimated completion is 2019-01-09.

What conditions does trial NCT02904096 study?

This clinical trial studies the following conditions: Volume Loss in the Dorsum of the Hand.

What interventions are being tested in trial NCT02904096?

The interventions under investigation include: Radiesse injectable implant and 2% lidocaine HCL (DEVICE).

Who is sponsoring clinical trial NCT02904096?

This trial is sponsored by Merz North America, which has 35 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02904096 being conducted?

This trial has 9 study locations across California, New York, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Volume Loss in the Dorsum of the Hand

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.